دورية أكاديمية
أعرض في EDS

In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.

التفاصيل البيبلوغرافية
العنوان: In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.
المؤلفون: Kayama S; Antimicrobial Resistance Research Centre, National Institute of Infectious Diseases, Higashimurayama City, Tokyo, Japan., Kawakami S; Antimicrobial Resistance Research Centre, National Institute of Infectious Diseases, Higashimurayama City, Tokyo, Japan., Kondo K; Antimicrobial Resistance Research Centre, National Institute of Infectious Diseases, Higashimurayama City, Tokyo, Japan., Kitamura N; Antimicrobial Resistance Research Centre, National Institute of Infectious Diseases, Higashimurayama City, Tokyo, Japan., Yu L; Antimicrobial Resistance Research Centre, National Institute of Infectious Diseases, Higashimurayama City, Tokyo, Japan., Hayashi W; Antimicrobial Resistance Research Centre, National Institute of Infectious Diseases, Higashimurayama City, Tokyo, Japan., Yahara K; Antimicrobial Resistance Research Centre, National Institute of Infectious Diseases, Higashimurayama City, Tokyo, Japan., Sugawara Y; Antimicrobial Resistance Research Centre, National Institute of Infectious Diseases, Higashimurayama City, Tokyo, Japan., Sugai M; Antimicrobial Resistance Research Centre, National Institute of Infectious Diseases, Higashimurayama City, Tokyo, Japan. Electronic address: sugai@niid.go.jp.
المصدر: Journal of global antimicrobial resistance [J Glob Antimicrob Resist] 2024 Sep; Vol. 38, pp. 12-20. Date of Electronic Publication: 2024 May 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer Country of Publication: Netherlands NLM ID: 101622459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-7173 (Electronic) Linking ISSN: 22137165 NLM ISO Abbreviation: J Glob Antimicrob Resist Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam : Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer
مواضيع طبية MeSH: beta-Lactamases*/genetics , beta-Lactamases*/metabolism , Cephalosporins*/pharmacology , Cefiderocol* , Bacterial Proteins*/genetics , Bacterial Proteins*/metabolism , Anti-Bacterial Agents*/pharmacology , Meropenem*/pharmacology , Microbial Sensitivity Tests* , Pseudomonas aeruginosa*/drug effects , Pseudomonas aeruginosa*/genetics , Pseudomonas aeruginosa*/enzymology , Gram-Negative Bacteria*/drug effects , Gram-Negative Bacteria*/genetics , Gram-Negative Bacteria*/enzymology , Whole Genome Sequencing* , Acinetobacter*/drug effects , Acinetobacter*/genetics , Acinetobacter*/isolation & purification, Japan ; Humans ; Drug Resistance, Multiple, Bacterial/genetics ; Gram-Negative Bacterial Infections/microbiology ; Azabicyclo Compounds/pharmacology ; Tazobactam/pharmacology ; Drug Combinations ; Imipenem/pharmacology ; Ceftazidime/pharmacology ; Epidemiological Monitoring
مستخلص: Objectives: The treatment options available for infections caused by multidrug-resistant Gram-negative pathogens are often limited. Cefiderocol (CFDC) is a novel siderophore cephalosporin that exhibits activity against these pathogens. Several studies have reported the in vitro activity of CFDC against isolates from Europe, the United States, and China, but the activity against carbapenem-resistant bacteria with IMP-type carbapenemase has not been extensively studied. We, therefore, studied the in vitro activities of CFDC against carbapenem-resistant bacteria with available genomic backgrounds based on whole-genome sequencing (WGS) in Japan, where the IMP-type is the predominant carbapenemase produced by Gram-negative rods.
Methods: We selected 603 isolates (528 Enterobacterales, 18 Pseudomonas aeruginosa, and 57 Acinetobacter spp.) from a collection of Gram-negative clinical isolates collected during a Japan Antimicrobial Resistance Bacterial Surveillance program and evaluated the antimicrobial activities of CFDC, ceftolozane/tazobactam (CTLZ/TAZ), imipenem-relebactam (IPM/REL), and ceftazidime/avibactam (CAZ/AVI) against carbapenemase-producing Enterobacterales, carbapenemase-non-producing meropenem-non-susceptible Enterobacterales, and carbapenemase-producing nonfermentative bacteria.
Results: Among these, 97.7% of carbapenemase-producing Enterobacterales (99.2% of IMP-type carbapenemase-producing Enterobacterales), 100% of carbapenemase-producing P. aeruginosa, and 91.2% of carbapenemase-producing Acinetobacter spp. were susceptible to CFDC, showing better antimicrobial activity than the other antimicrobial agents evaluated in this study. CFDC was highly effective against class A-, B-, and D β-lactamase-harbouring isolates when compared to the other antimicrobial agents. In addition, the relationship between CFDC resistance and three genetic factors involved in resistance was discussed.
Conclusions: This is the first large-scale study to systematically demonstrate the efficacy of CFDC against IMP-type carbapenemase-producing strains with known genomic backgrounds.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
فهرسة مساهمة: Keywords: Cefiderocol; CirA; NDM; Penicillin-binding protein 3
المشرفين على المادة: EC 3.5.2.6 (beta-Lactamases)
0 (Cephalosporins)
EC 3.5.2.6 (carbapenemase)
SZ34OMG6E8 (Cefiderocol)
0 (Bacterial Proteins)
0 (Anti-Bacterial Agents)
FV9J3JU8B1 (Meropenem)
0 (Azabicyclo Compounds)
0 (ceftolozane, tazobactam drug combination)
SE10G96M8W (Tazobactam)
0 (Drug Combinations)
0 (avibactam, ceftazidime drug combination)
71OTZ9ZE0A (Imipenem)
9M416Z9QNR (Ceftazidime)
تواريخ الأحداث: Date Created: 20240524 Date Completed: 20240912 Latest Revision: 20240912
رمز التحديث: 20240913
DOI: 10.1016/j.jgar.2024.05.009
PMID: 38789082
قاعدة البيانات: MEDLINE
الوصف
تدمد:2213-7173
DOI:10.1016/j.jgar.2024.05.009